All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lymphoma & CLL content recommended for you
The FDA grants copanlisib Priority Review for the possible treatment of relapsed/refractory Follicular Lymphoma
On 17th May 2017, copanlisib (BAY 80-6946), a pan-class I PI3K inhibitor, was granted Priority Review by the U.S. Food and Drug Administration (FDA) for the treatment of R/R FL patients who have received ≥2 previous treatments.
This regulatory submission was based on results of the pivotal CHRONOS-1 phase II trial, which aimed to assess the safety and efficacy of copanlisib in 141 patients with R/R iNHL. Primary results for the whole patient cohort were presented at this year’s American Association for Cancer Research (AACR) annual meeting, which the Lymphoma Hub reported on last month. Data specifically from patients with FL will be presented at this year’s American Society of Clinical Oncology (ASCO) annual meeting in June.
Bayer’s copanlisib has already been awarded Fast Track and Orphan Drug designations by the FDA for R/R FL.
References